Besides cardioprotective effects, the AT1R (angiotensin-II type 1 receptor) antagonist losartan protects the liver from IRI [IR (ischaemia/reperfusion) injury], but the mechanism has not been fully determined. The HIF (hypoxia inducible factor)-1α and Wnt/β-catenin signalling pathways have been reported to be involved in the mechanism of liver IRI. Therefore the aim of the present study was to determine whether the Wnt/HIF axis is part of the mechanism of the positive effect of AngII inhibition by losartan in liver IRI in rats. Various measurements were made in MCD/HF-NASH (methionine- and choline-deficient-diet/high-fat-diet-induced non-alcoholic steatohepatitis) rats with liver IRI. Acute losartan pre-administration markedly reversed the IR-suppressed levels of the hepatic-protective factors IL (interleukin)-6, IFN (interferon)-γ, Wnt3a, β-catenin and HIF-1α, and decreased hepatic blood flow and IR-elevated serum ALT (alanine aminotransferase), hepatic TNF (tumour necrosis factor)-α, IL-1α, hepatic congestion, vacuolization and necrosis, hepatic Suzuki IRI scores, necrotic index and levels of TBARS (thiobarbituric acid-reacting substances) in MCD/HF-NASH rats. Furthermore, acute Wnt3a pre-treatment significantly inhibited IR-elevated serum ALT, hepatic Suzuki IRI scores and TBARS, and restored the IR-depleted β-catenin/HIF-1α activity in MCD/HF-NASH rats. Simultaneous acute sFRP2 (secreted frizzled-related protein 2; a Wnt3a inhibitor) pre-treatment eliminated the losartan-related beneficial effects in MCD/HF-NASH rats with liver IRI, which was accompanied by a decrease in hepatic HIF-1α/β-catenin activity. Losartan-induced up-regulation of HIF-1α and Wnt/β-catenin signalling was associated with the recovery of IR-inhibited hepatic Bcl-2, Mn-SOD (manganese superoxide), Cu/Zn-SOD (copper/zinc superoxide) and GSH levels, and the suppression of IR-increased hepatic catalase and caspase 3/caspase 8 levels in MCD/HF-NASH rats. In conclusion, up-regulation of the HIF-1α and Wnt/β-catenin signalling pathways are part of the mechanism of the positive effects of losartan-related AngII inhibition in MCD/HF-NASH rats with liver IRI. Our study highlights the potential of the dual-organ protective agent losartan in NASH patients with steatotic livers and cardiovascular risk.
Skip Nav Destination
Article navigation
Research Article|
September 23 2013
Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury
Ying-Ying Yang;
Ying-Ying Yang
1
*Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Correspondence: Dr Ying-Ying Yang (email [email protected]) or Professor Han-Chieh Lin (email [email protected])
Search for other works by this author on:
Pei-Chang Lee;
Pei-Chang Lee
†Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for other works by this author on:
Yi-Tsau Huang;
Yi-Tsau Huang
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
§National Research Institute of Chinese Medicine, Taipei, Taiwan
Search for other works by this author on:
Wei-Ping Lee;
Wei-Ping Lee
†Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for other works by this author on:
Ying-Ju Kuo;
Ying-Ju Kuo
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
¶Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan
Search for other works by this author on:
Kuei-Chuan Lee;
Kuei-Chuan Lee
†Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for other works by this author on:
Yun-Cheng Hsieh;
Yun-Cheng Hsieh
†Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for other works by this author on:
Tzung-Yan Lee;
Tzung-Yan Lee
∥Graduate Institute of Traditional Chinese Medicine, Chang Gung University, Taipei, Taiwan
Search for other works by this author on:
Han-Chieh Lin
Han-Chieh Lin
1
†Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
‡Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Correspondence: Dr Ying-Ying Yang (email [email protected]) or Professor Han-Chieh Lin (email [email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 14 2013
Revision Received:
June 11 2013
Accepted:
July 23 2013
Accepted Manuscript online:
July 23 2013
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2014 Biochemical Society
2014
Clin Sci (Lond) (2014) 126 (2): 163–174.
Article history
Received:
January 14 2013
Revision Received:
June 11 2013
Accepted:
July 23 2013
Accepted Manuscript online:
July 23 2013
Citation
Ying-Ying Yang, Pei-Chang Lee, Yi-Tsau Huang, Wei-Ping Lee, Ying-Ju Kuo, Kuei-Chuan Lee, Yun-Cheng Hsieh, Tzung-Yan Lee, Han-Chieh Lin; Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury. Clin Sci (Lond) 1 January 2014; 126 (2): 163–174. doi: https://doi.org/10.1042/CS20130025
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |